Photo from Antonio Giordano/X
May 16, 2025, 11:26
Antonio Giordano: Important question – which 1L CDK4/6i to preserve efficacy of re-cycling cell cycle in 2L?
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, on X, adding:
“Important question: which 1L CDK4/6i to preserve efficacy of re-cycling cell cycle in 2L? What biomarkers can predict response to recycle cell cycle?”
Quoting Erika Hamilton’s post:
“Cristina Saura presents EMBER3 by prior CDK4/6.
Constant benefit among those with prior CDK, very important data in 2025 where most will get CDK in 1st line- 3.7 vs. 9.1 months.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 10:25
May 16, 2025, 09:25
May 16, 2025, 09:10